Brief: Vertex Announces UK Mhra Approval Of Alyftrek
07/03/2025 16:32
March 7 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O: VERTEX ANNOUNCES UK MHRA APPROVAL OF ALYFTREK® (DEUTIVACAFTOR/TEZACAFTOR/VANZACAFTOR), A ONCE-DAILY NEXT-IN-CLASS CFTR MODULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS VERTEX PHARMACEUTICALS INC - WORKING WITH NICE AND NHS FOR ALYFTREK ACCESS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31